Benjamin F. McGraw III

Dr. McGraw is chairman and chief executive officer of TheraVida, Inc., a private pharmaceutical company focused on therapies for dermatologic diseases, since 2011 and 2013, respectively. Dr. McGraw has served as executive chairman of Auration Biotech, Inc., a private biotechnology company focused on a regenerative protein and other therapies for ear, nose, and throat diseases since 2014. Dr. McGraw is the lead independent director for the board of directors of Aerie Pharmaceuticals, Inc., a public pharmaceutical company focused on new treatments for glaucoma and other diseases of the front and back of the eye. He is also executive chairman of Trefoil Therapeutics, Inc., a private biopharmaceutical company focused on developing an engineered protein as a regenerative treatment for corneal endothelial dystrophies and epithelial disorders. Previously, Dr. McGraw served as the managing member of Long Shadows Asset Management, LLC, an investment advisory company; chairman, president, and CEO of Valentis, Inc., a public gene therapy company; corporate vice president of corporate development at Allergan, Inc., a public pharmaceutical company; and VP of Development at Marion Laboratories, Inc., and Marion Merrell Dow, Inc., both public pharmaceutical companies. Dr. McGraw received his BS and his Doctor of Pharmacy degree from the University of Tennessee Health Science Center, where he also completed a clinical practice residency.